Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors

Synapse

Volumn 34, Issue 4, 1999, Pages 290-304

  Fujita, Masahiro ^a,d   Seibyl, John P ^a   Verhoeff, N Paul L G ^a   Ichise, Masanori ^b   Baldwin, Ronald M ^a   Zoghbi, Sami S ^a   Burger, Cyrill ^c   Staley, Julie K ^a   Rajeevan, Nallakkandi ^a   Charney, Dennis S ^a   Innis, Robert B ^a  

^a YALE UNIVERSITY   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Compartment modeling; Lipophilic metabolites; SPECT

Indexed keywords

DOPAMINE 2 RECEPTOR; EPIDEPRIDE;

ADULT; ARTICLE; BRAIN REGION; CLINICAL TRIAL; COMPARTMENT MODEL; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BENZAMIDES; CEREBELLUM; FEMALE; HUMANS; KINETICS; MALE; MATHEMATICS; MODELS, BIOLOGICAL; NEOSTRIATUM; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TEMPORAL LOBE; THERMODYNAMICS; TIME FACTORS;

EID: 0033573243     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(19991215)34:4<290::AID-SYN5>3.0.CO;2-B     Document Type: Article

References (34)

1. 123I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35:228-238.
2. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Contr AC19:716-723.
3. 123I]2′-ISP in nonhuman primates. Nucl Med Biol 21:969-976.
4. 123I]epidepride in human plasma determined with a gradient HPLC method. J Label Compound Radiopharrn 40:151-153.
5. 2 receptors in humans using positron emission tomography. Eur J Nucl Med 21:937-946.
6. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42.
7. 2 dopamine receptors studied with PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708.
8. Friston KJ, Ashburner J, Poline JB, Frith CD, Heather JD, Frackowiak RSJ. 1995. Spatial registration and normalisation of images. Human Brain Map 2:165-189.
9. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrfiltration for the free fraction determination of single photon emission computed tomography (SPECT) tracers: ß-CIT IBF, and iomazenil. J Pharm Sci 83:1014-1019.
10. 2 dopamine receptors in the temporal lobe in schizophrenia: a postmortem study. Arch Gen Psychiatry 54:649-658.
11. 125I]epidepride. Synapse 23:115-123.
12. Hawkins RA, Phelps ME, Huang S-C. 1986. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab 6:170-183.
13. 18F]fluoro-DOPA in human positron emission tomographic studies. J Cereb Blood Flow Metab 11:898-913.
14. Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, Belknap JK. 1992. Extrastriatal dopamine D2 receptors: Distribution, pharmacological characterization and region-specific regulation by clozapine. J Pharamacol Exp Ther 261:1282-1290.
15. 125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 49:617-628.
16. 2 receptors in the human brain. Eur J Pharmacol 223:105-107.
17. 18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors. Synapse 15:169-176.
18. 125I]epidepride. Brain Res 609:237-243.
19. 123I]epidepride: characterization of uptake in the human brain. J Neural Transm 101:95-103.
20. 123I]epidepride single-photon emission tomography. Eur J Nucl Med 24:483-487.
21. 18F]fluoro-DOPA and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 13:43-56.
22. 123I]ß-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14:982-994.
23. Lidow MS, Goldman-Rakic PS. 1994. A common action of clozapine, haloperidol and remoxipride on D1- and D2-dopamine receptors in primate cerebral cortex. Proc Natl Acad Sci USA 91:4353-4356.
24. Lidow MS, Goldman-Rakic PS, Rakic P, Innis RB. 1989. Dopamine D2 receptors in the cerebral cortex: Distribution and pharmacological characterization with 3H-raclopride. Proc Natl Acad Sci USA 86: 6412-6416.
25. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227.
26. Mintun MA, Price JP, Smith GS, Lopresti B, Hartman L, Simpson N, Mathis CA. 1996. Quantitative 5-HT2A receptor imaging in man using F-18 altanserin: a new model accounting for labeled metabolites. J Nucl Med Suppl:109P.
27. 3 receptors. Eur J Pharmacol 238:121-125.
28. 18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22:283-296.
29. 2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91:11271-11275.
30. 2 receptors and receptor functions in the rat. Pharmacol Toxicol 73:325-334.
31. 123I-epidepride and the bolus/infusion approach. J Cereb Blood Flow Metab 17:S3.
32. Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L, Podreka I, Brucke T. 1997. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 38:1711-1717.
33. Votaw JR, Kessler RM, de Paulis T. 1993, Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. Synapse 15:177-190.
34. Woods RP, Mazziotta JC, Cherry SR. 1993. MRI-PET registration with automated algorithm. J Comp Assist Tomogr 17:536-546.